Literature DB >> 19500759

Pathogenesis of primary adrenal insufficiency.

Eystein Husebye1, Kristian Løvås.   

Abstract

Autoimmune Addison's disease is caused by autoreactivity towards the adrenal cortex involving 21-hydroxylase autoantibodies and autoreactive T cells. Autoimmune destruction of the adrenal cortex is triggered by hitherto unknown environmental factors in individuals with genetic susceptibility. Several genes have been identified, of which the major histocompatibility complex haplotypes DR3-DQ2 and DR4-DQ8 are most strongly associated. In addition, other genes also implicated in other autoimmune diseases are linked to Addison's disease, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), protein tyrosine phosphatase non-receptor type 22 (PTPN22), major histocompatibility complex class II transactivator (CIITA), and most recently the C-lectin type gene (CLEC16A). Studies employing T cells in humans and animal models, and the collection of large patient cohorts facilitating genome-wide screening projects, will hopefully improve the understanding of the pathogenesis of the disease in the near future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500759     DOI: 10.1016/j.beem.2008.09.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  11 in total

Review 1.  Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status.

Authors:  Yu-Cheng Huang; Yu-Lian Tang; Xiao-Ming Zhang; Nan-Lin Zeng; Rui Li; Tian-Wu Chen
Journal:  World J Radiol       Date:  2015-10-28

2.  DLA class II haplotypes show sex-specific associations with primary hypoadrenocorticism in Standard Poodle dogs.

Authors:  Amy E Treeful; Aaron K Rendahl; Steven G Friedenberg
Journal:  Immunogenetics       Date:  2019-04-09       Impact factor: 2.846

Review 3.  Diagnosis and management of pediatric adrenal insufficiency.

Authors:  Ahmet Uçar; Firdevs Baş; Nurçin Saka
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

Review 4.  Adrenal cortical insufficiency--a life threatening illness with multiple etiologies.

Authors:  Marcus Quinkler; Felix Beuschlein; Stefanie Hahner; Gesine Meyer; Christof Schöfl; Günter K Stalla
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

5.  Screening for associated autoimmune disorders in Polish patients with Addison's disease.

Authors:  Marta Fichna; Piotr Fichna; Maria Gryczyńska; Jarosław Walkowiak; Magdalena Zurawek; Jerzy Sowiński
Journal:  Endocrine       Date:  2010-03-16       Impact factor: 3.633

6.  Polymorphisms in the CTLA4 promoter sequence are associated with canine hypoadrenocorticism.

Authors:  Alisdair M Boag; Andrea Short; Lorna J Kennedy; Hattie Syme; Peter A Graham; Brian Catchpole
Journal:  Canine Med Genet       Date:  2020-03-04

7.  CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner.

Authors:  Mark O Huising; Talitha van der Meulen; Joan M Vaughan; Masahito Matsumoto; Cynthia J Donaldson; Hannah Park; Nils Billestrup; Wylie W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 8.  [Addison's disease].

Authors:  M Quinkler
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-22       Impact factor: 0.840

Review 9.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

10.  Autoantibodies against Cytochrome P450 Side-Chain Cleavage Enzyme in Dogs (Canis lupus familiaris) Affected with Hypoadrenocorticism (Addison's Disease).

Authors:  Alisdair M Boag; Michael R Christie; Kerry A McLaughlin; Harriet M Syme; Peter Graham; Brian Catchpole
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.